Ixiaro (Japanese Encephalitis Vaccine, Inactivated, Adsorbed) Drug Interactions
Check all documented drug-to-drug interactions. Major, moderate, and minor interactions with descriptions.
A therapy excluded from this list does not necessarily mean no interaction exists between that therapy and Ixiaro. Always confirm against the full prescribing information.
100 interactions
Abatacept
The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Abatacept.
Level 2 evidence
Adalimumab
The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Adalimumab.
Level 2 evidence
Aldesleukin
The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Aldesleukin.
Level 2 evidence
Alemtuzumab
The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Alemtuzumab.
Level 2 evidence
Anakinra
The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Anakinra.
Level 2 evidence
Anifrolumab
The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Anifrolumab.
Level 2 evidence
Antilymphocyte immunoglobulin (horse)
The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Antilymphocyte immunoglobulin (horse).
Level 2 evidence
Antithymocyte immunoglobulin (rabbit)
The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).
Level 2 evidence
Apremilast
The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Apremilast.
Level 2 evidence
Arsenic trioxide
The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Arsenic trioxide.
Level 2 evidence
Avacincaptad pegol
The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Avacincaptad pegol.
Level 2 evidence
Avacopan
The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Avacopan.
Ixiaro (Japanese Encephalitis Vaccine, Inactivated, Adsorbed) has 224 documented drug interactions. Always review the full list with a pharmacist before co-prescribing.
Ixiaro (Japanese Encephalitis Vaccine, Inactivated, Adsorbed) has 0 major, 223 moderate, and 1 minor documented interactions.
A therapy excluded from this list does not necessarily mean no interaction exists between that therapy and Ixiaro. Always confirm against the full prescribing information.